Arrowhead price target lowered to $59 from $65 at B. Riley

B. Riley analyst Mayank Mamtani lowered the firm’s price target on Arrowhead Pharmaceuticals to $59 from $65 and keeps a Buy rating on the shares. Arrowhead reported Q4 results and provided detailed updates to its RNAi therapeutics pipeline, constituting of 11 wholly owned and partnered clinical-stage programs that the company guided for expansion to a total 20 in 2025 while maintaining the goal of reaching one new cell type in every 12-18 months, Mamtani tells investors in a research note. "What’s even more impressive is remarkably the lack of any failed/discontinued program based on clinical data generated," writes the analyst.